β-榄香烯增强紫杉醇对卵巢癌OVCAR3细胞凋亡的促进作用  

β-elemene enhances paclitaxel-induced apoptosis of ovarian cancer cell OVCAR3

作　　者：王峥嵘[1] 郭洁[2] 范焕芳[1] 李德辉[1] WANG Zheng-rong;GUO Jie;FAN Huan-fang;LI De-hui(Department of Oncology,Traditional Chinese Medicine Hospital,Shijiazhuang 050051,Hebei Province,China;Department ofRespiratory,Traditional Chinese Medicine Hospital,Shijiazhuang 050051,Hebei Province,China)

机构地区：[1]河北省中医院肿瘤二科,河北石家庄050051 [2]河北省中医院呼吸科,河北石家庄050051

出　　处：《中国临床药理学杂志》2020年第18期2861-2864,2868,共5页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然科学基金资助项目(81603412);河北省自然科学基金资助项目(H2018423026)。

摘　　要：目的研究β-榄香烯联合紫杉醇对卵巢癌的治疗价值,并初步探讨β-榄香烯对卵巢癌OVCAR3细胞凋亡影响的潜在机制。方法将确诊的90例晚期卵巢癌患者随机分为试验组与对照组,各45例。对照组于第1,7天静脉滴注紫杉醇75 mg·m-2,2 h内滴注完毕;试验组在对照组的基础上给予β-榄香烯400~600 mg,溶入5%葡萄糖注射液400~500 mL,静脉滴注,每日1次,共治疗2周。比较2组患者的治疗有效率、疾病控制率和死亡率。取对数生长期OVCAR3细胞,分为5组:10 mg·L^-1紫杉醇组、10 mg·L^-1紫杉醇+50 mg·L^-1β-榄香烯组、10 mg·L^-1紫杉醇+800 mg·L^-1β-榄香烯组、10 mg·L^-1紫杉醇+3200 mg·L^-1β-榄香烯组、磷酸缓冲盐溶液(phosphate buffer saline,PBS)组,每组5个复孔。以CCK-8实验检测培养24,48和72 h时的细胞活性;以流式细胞术分析细胞凋亡水平;以Western blotting检测蛋白水平。结果对照组的有效率和疾病控制率分别为37.78%,64.44%,明显低于试验组的62.22%和86.67%,差异有统计学意义(P<0.05)。培养72 h,PBS组、10 mg·L^-1紫杉醇组、10 mg·L^-1紫杉醇+50 mg·L^-1β-榄香烯组、10 mg·L^-1紫杉醇+800 mg·L^-1β-榄香烯组、10 mg·L^-1紫杉醇+3200 mg·L^-1β-榄香烯组的细胞存活率分别为(99.69±0.30)%,(49.11±3.19)%,(36.04±2.88)%,(23.26±2.33)%,(19.25±1.48)%,凋亡率分别为(0.29±0.03)%,(22.26±3.00)%,(37.21±3.42)%,(46.11±3.53)%,(51.34±4.03)%,差异均有统计学意义(均P<0.05)。结论联合应用β-榄香烯与紫杉醇对卵巢癌具有较好的治疗作用,该作用可能是通过抑制JAK2/STAT1通路实现。Objective To explore the therapeutic value ofβ-elemene combined with paclitaxel in ovarian cancer,and to explore the potential mechanism ofβ-elemene on the apoptosis of ovarian cancer OVCAR3 cells.Methods A total of 90 patients with advanced ovarian cancer were randomly divided into treatment group(n=45)and control group(n=45).Control group was treated with paclitaxel on the 1 st and 7 th day,paclitaxel 75 mg·m-2 was intravenously administered,and the instillation was completed within 2 h.Treatment group was givenβ-elemene 400-600 mg,dissolved in 5%glucose injection 400-500 mL,intravenously,once a day,on the basis of control group.Two groups were all treated for 2 weeks.The treatment efficacy,disease control rate,and mortality during treatment were compared between the two groups.The human ovarian cancer cell line OVCAR3 was cultured to logarithmic growth phase,and divided into 5 groups:10 mg·L^-1 paclitaxel group,10 mg·L^-1 paclitaxel+50 mg·L^-1β-elemene group,10 mg·L^-1 paclitaxel+800 mg·L^-1β-elemene group,10 mg·L^-1 paclitaxel+3200 mg·L^-1β-elemene group,phosphate buffer saline(PBS)group,5 replicate wells per group.The cell viability at 24,48 and 72 h were detected by CCK-8 assay.The level of apoptosis was analyzed by flow cytometry.The protein level was detected by Western blotting.Results The effective rateand disease control ratein control group were 37.78%,64.44%,significantly lower than those in treatment group,which were 62.22%,86.67%,with significant difference(P<0.05).The cell survival rates of at72 h in PBS group,10 mg·L^-1 paclitaxel group,10 mg·L^-1 paclitaxel+50 mg·L^-1β-elemene group,10 mg·L^-1 paclitaxel+800 mg·L^-1β-elemene group,10 mg·L^-1 paclitaxel+3200 mg·L^-1β-elemene group were(99.69±0.30)%,(49.11±3.19)%,(36.04±2.88)%,(23.26±2.33)%,(19.25±1.48)%,the apoptosis rates were(0.29±0.03)%,(22.26±3.00)%,(37.21±3.42)%,(46.11±3.53)%,(51.34±4.03)%,all with significant difference(all P<0.05).Conclusion The combination ofβ-elemene and paclitaxel has a good therapeuti

关 键 词：Β-榄香烯 卵巢癌 紫杉醇 增殖 凋亡 

分 类 号：R28[医药卫生—中药学]